Hui Zhang1,2, Alex Iranzo3, Birgit Högl4, Isabelle Arnulf5, Luigi Ferini-Strambi6, Raffaele Manni7, Tomoyuki Miyamoto8, Wolfgang H Oertel9, Yves Dauvilliers10, Yo-Ei Ju11, Monica Puligheddu12, Karel Sonka13, Amélie Pelletier14, Jacques Y Montplaisir14,15, Ambra Stefani4, Abubaker Ibrahim4, Birgit Frauscher4, Smaranda Leu-Semenescu5, Marco Zucconi6, Michele Terzaghi7, Masayuki Miyamoto16, Annette Janzen9, Michela Figorilli12, Maria L Fantini12,17, Ronald B Postuma2,14. 1. Department of Neurology, Xuanwu Hospital Capital Medical University, Beijing, China. 2. Department of Neurology, McGill University, Montreal General Hospital, Montreal, Quebec, Canada. 3. Neurology Service, Hospital Clinic of Barcelona, August Pi i Sunyer Biomedical Research Institute, Center for Biomedical Research on Neurodegenerative Diseases, Barcelona, Spain. 4. Department of Neurology, Innsbruck Medical University, Innsbruck, Austria. 5. Paris Brain Institute and Sleep Disorder Unit, Pitié-Salpêtrière Hospital, Public Hospital Network of Paris, Sorbonne University, Paris, France. 6. Sleep Disorders Center, Vita-Salute San Raffaele University, Milan, Italy. 7. C. Mondino National Neurological Institute, Pavia, Italy. 8. Department of Neurology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan. 9. Department of Neurology, Philipps University, Marburg, Germany. 10. Department of Neurology, Gui de Chauliac Hospital, Montpellier, National Institute of Health and Medical Research U1061, Montpellier, France. 11. Department of Neurology, Washington University School of Medicine, St Louis, MO, USA. 12. Sleep Center, Department of Cardiovascular and Neurological Sciences, University of Cagliari, Cagliari, Italy. 13. Department of Neurology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. 14. Center for Advanced Studies in Sleep Medicine, Montreal Sacred Heart Hospital, Montreal, Quebec, Canada. 15. Department of Psychiatry, University of Montreal, Montreal, Quebec, Canada. 16. Department of Neurology, Dokkyo Medical University School of Medicine, Tochigi, Japan. 17. Department of Neurology, University of Auvergne, Clermont-Ferrand, France.
Abstract
OBJECTIVE: This study was undertaken to follow up predictive factors for α-synuclein-related neurodegenerative diseases in a multicenter cohort of idiopathic/isolated rapid eye movement sleep behavior disorder (iRBD). METHODS: Patients with iRBD from 12 centers underwent a detailed assessment for potential environmental and lifestyle risk factors via a standardized questionnaire at baseline. Patients were then prospectively followed and received assessments for parkinsonism or dementia during follow-up. The cumulative incidence of parkinsonism or dementia was estimated with competing risk analysis. Cox regression analyses were used to evaluate the predictive value of environmental/lifestyle factors over a follow-up period of 11 years, adjusting for age, sex, and center. RESULTS: Of 319 patients who were free of parkinsonism or dementia, 281 provided follow-up information. After a mean follow-up of 5.8 years, 130 (46.3%) patients developed neurodegenerative disease. The overall phenoconversion rate was 24.2% after 3 years, 44.8% after 6 years, and 67.5% after 10 years. Patients with older age (adjusted hazard ratio [aHR] = 1.05) and nitrate derivative use (aHR = 2.18) were more likely to phenoconvert, whereas prior pesticide exposure (aHR = 0.21-0.64), rural living (aHR = 0.53), lipid-lowering medication use (aHR = 0.59), and respiratory medication use (aHR = 0.36) were associated with lower phenoconversion risk. Risk factors for those converting to primary dementia and parkinsonism were generally similar, with dementia-first converters having lower coffee intake and beta-blocker intake, and higher occurrence of family history of dementia. INTERPRETATION: Our findings elucidate the predictive values of environmental factors and comorbid conditions in identifying RBD patients at higher risk of phenoconversion. ANN NEUROL 2022;91:404-416.
OBJECTIVE: This study was undertaken to follow up predictive factors for α-synuclein-related neurodegenerative diseases in a multicenter cohort of idiopathic/isolated rapid eye movement sleep behavior disorder (iRBD). METHODS: Patients with iRBD from 12 centers underwent a detailed assessment for potential environmental and lifestyle risk factors via a standardized questionnaire at baseline. Patients were then prospectively followed and received assessments for parkinsonism or dementia during follow-up. The cumulative incidence of parkinsonism or dementia was estimated with competing risk analysis. Cox regression analyses were used to evaluate the predictive value of environmental/lifestyle factors over a follow-up period of 11 years, adjusting for age, sex, and center. RESULTS: Of 319 patients who were free of parkinsonism or dementia, 281 provided follow-up information. After a mean follow-up of 5.8 years, 130 (46.3%) patients developed neurodegenerative disease. The overall phenoconversion rate was 24.2% after 3 years, 44.8% after 6 years, and 67.5% after 10 years. Patients with older age (adjusted hazard ratio [aHR] = 1.05) and nitrate derivative use (aHR = 2.18) were more likely to phenoconvert, whereas prior pesticide exposure (aHR = 0.21-0.64), rural living (aHR = 0.53), lipid-lowering medication use (aHR = 0.59), and respiratory medication use (aHR = 0.36) were associated with lower phenoconversion risk. Risk factors for those converting to primary dementia and parkinsonism were generally similar, with dementia-first converters having lower coffee intake and beta-blocker intake, and higher occurrence of family history of dementia. INTERPRETATION: Our findings elucidate the predictive values of environmental factors and comorbid conditions in identifying RBD patients at higher risk of phenoconversion. ANN NEUROL 2022;91:404-416.
Authors: Yaping Liu; Eemil Partinen; Ngan Yin Chan; Yves Dauvilliers; Yuichi Inoue; Luigi De Gennaro; Giuseppe Plazzi; Courtney J Bolstad; Michael R Nadorff; Ilona Merikanto; Bjørn Bjorvatn; Fang Han; Bin Zhang; Ana Suely Cunha; Sérgio Mota-Rolim; Damien Léger; Kentaro Matsui; Colin A Espie; Frances Chung; Charles M Morin; Mariusz Sieminski; Penzel Thomas; Brigitte Holzinger; Markku Partinen; Yun Kwok Wing Journal: J Sleep Res Date: 2022-04-26 Impact factor: 5.296
Authors: Li Zhou; Steven W H Chau; Yaping Liu; Jing Wang; Jihui Zhang; Ngan Yin Chan; Joey W Y Chan; Bei Huang; Sijing Chen; Shirley Xin Li; Vincent Chung Tong Mok; Yun Kwok Wing Journal: NPJ Parkinsons Dis Date: 2022-07-14